CONMED Q4 sales $327M (+30.4% YoY); adjusted EPS $1.06 (+152%); guides FY24 rev $1.34-1.365B

CONMED Corp

2023-FY EPS reported $2.04 revenue$1,244,744,000

Q4 sales $327.0M, +30.4% YoY (31.5% constant currency); domestic +33.3%, intl +26.5% as reported.
Q4 GAAP diluted EPS $1.05; adjusted diluted EPS $1.06, up 152.4% vs Q4 2022.
FY2023 sales $1,244.7M (+19.1%); GAAP EPS $2.04 vs loss of $2.68; adjusted EPS $3.45 (+30.2%).
FY2024 revenue guidance $1.340B-$1.365B (8-10% growth); adjusted EPS guidance $4.30-$4.40 (25-28% growth).
Record revenue achieved in both Q4 and full year; balanced growth across General Surgery and Orthopedics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

CONMED Corp reported financial results for the fourth quarter and full-year ended December 31, 2023.

Period: the fourth quarter and full-year ended December 31, 2023
Result: reported results

Exact text from the filing

On January 31, 2024, CONMED Corporation issued a press release announcing financial results for the fourth quarter ended December 31, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

CONMED Corp filing history →

Source: SEC EDGAR

accession 0001174947-24-000144

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.